viral load

Related by string. Viral Load * Viral . virals . VIRAL . Virals : viral loads . inhibit viral replication . viral infection . viral infections . viral replication . Goes Viral . suppress viral replication / Load . LOA . Loa . LOAD . LoA . Loas . LOAs : load balancing . load balancer . Waste Allocation Load . axle load . Load Balancing . Load balancing . unscheduled load shedding * undetectable viral load *

Related by context. All words. (Click for frequent words.) 79 viral loads 77 HCV RNA 73 HBV DNA 72 HIV RNA 71 CD4 cell 70 viral suppression 69 undetectable viral load 69 copies mL 68 CD4 counts 66 virologic failure 66 HAART 65 seroconversion 65 IU mL 65 copies ml 65 CD4 count 64 virologic response 64 CD4 64 viremia 63 serum HBV DNA 63 serum HCV RNA 63 CD4 + cell 63 antiretroviral therapy 63 sustained virologic response 62 CD4 + T 62 platelet counts 62 HbA1c levels 62 HBV DNA levels 62 plasma HCV RNA 62 virologic 61 cART 61 disease progression 61 antiviral activity 61 log# copies mL 61 virological response 61 log# 60 undetectable HCV RNA 60 HbA1c 60 HCV 60 Viral load 60 undetectable viral loads 60 raltegravir 60 CD4 T 60 antibody titers 60 neutrophil counts 60 peginterferon 60 plasma concentrations 59 HCV infected 59 log# reduction 59 antibody responses 59 virologic suppression 59 viraemia 59 viral replication 59 CD4 cells 59 tipranavir 59 titers 59 HCV viral 59 nelfinavir 58 TDF FTC 58 sustained virological response 58 antiviral therapy 58 antiviral efficacy 58 darunavir 58 antibody titer 58 median CD4 58 viral titer 58 lopinavir 58 HIV infection 58 atazanavir 58 tipranavir ritonavir 58 hepatitis C virus 58 fosamprenavir 58 seropositive patients 58 lamivudine 57 HCV genotype 1 57 rapid virologic response 57 proteinuria 57 virological suppression 57 detectable HCV RNA 57 HBeAg seroconversion 57 ribavirin 57 serum potassium 57 HCV genotype 57 potent antiretroviral therapy 57 lymphocyte counts 57 antiretroviral naive 57 adefovir 57 CD8 responses 57 genotypic resistance 57 tenofovir 57 CD4 + 57 pegylated interferon 57 recurrent genital herpes 57 LEXIVA r 57 plasma viremia 57 enfuvirtide 57 ritonavir boosted 57 Gag polymorphisms 57 antiretroviral therapy ART 57 HbA1C 57 serum concentrations 57 LPV r 57 neutrophil count 56 virologic response EVR 56 HBsAg 56 serum creatinine levels 56 valacyclovir 56 renal function 56 HIV infected 56 lymphocyte count 56 titer 56 atazanavir ritonavir 56 virologic responses 56 serum phosphorus 56 NNRTI 56 A1C levels 56 NNRTI resistance 56 SIV infection 56 baseline CD4 56 entecavir 56 creatinine levels 56 Vacc 4x 56 hemoglobin concentrations 56 lopinavir r 56 serum creatinine 56 ribavirin therapy 55 APTIVUS r 55 antiretroviral naïve 55 serum urate 55 darunavir ritonavir 55 undetectable HBV DNA 55 ARV therapy 55 HI titers 55 antiretroviral regimen 55 anti HBs 55 platelet reactivity 55 sUA 55 peginterferon alfa 2a 55 glomerular filtration rate 55 IU ml 55 coinfected 55 LEXIVA 55 HBeAg negative 55 platelet count 55 virological failure 55 protease inhibitor PI 55 ritonavir 55 serum phosphate 55 nucleotide analog 55 eGFR 55 vicriviroc 55 Hb A1C 55 HAART regimens 55 NRTI 55 FEV1 55 lopinavir ritonavir 55 TMC# [001] 55 HIV seroconversion 55 lumbar spine BMD 55 interferon 55 seropositivity 55 undetectable viral 54 indinavir 54 virologically 54 saquinavir 54 plasma uric acid 54 genotype 54 alanine aminotransferase ALT 54 biochemical relapse 54 low dose ritonavir 54 viral kinetics 54 serum urate levels 54 liver enzymes 54 dose cyclophosphamide 54 neutralizing antibody 54 seronegative 54 progression TTP 54 blood Phe levels 54 PSADT 54 baseline HbA1c 54 Pegasys plus Copegus 54 protease inhibitor 54 HBeAg 54 microliter 54 mg kg dose 54 Cmax 54 pg ml 54 immune responses 54 seroconverted 54 mg dose 54 thyroid stimulating hormone 54 complete cytogenetic response 54 hemoglobin concentration 54 liver histology 54 ABC/3TC 54 serum testosterone 54 dose cohorts 54 HAART regimen 54 abacavir lamivudine 54 CD4 + cells 54 PREZISTA r 54 cells mcL 54 glycated hemoglobin levels 54 CMV infection 54 mcg dose 54 fasting plasma glucose FPG 54 adiponectin levels 54 HBeAg positive 54 HCV replicon 54 tipranavir r 54 peginterferon alfa 2b 54 median PFS 54 experienced virologic failure 54 lactate dehydrogenase LDH 54 statistically significant p 54 CD4s 54 cells/mm3 54 REYATAZ r 54 BARACLUDE ® 54 viral titers 54 IgM 53 cells μL 53 Kaplan Meier analysis 53 ISENTRESS 53 severe neutropenia 53 CD4 lymphocyte count 53 antiretroviral 53 adalimumab 53 seroprotection 53 peripheral blood mononuclear 53 Virologic 53 efavirenz 53 neutralizing antibodies 53 comparator PI r 53 imatinib therapy 53 null responders 53 CCR5 tropic HIV 53 plasma glucose 53 seropositive 53 immunogenicity 53 creatinine ratio 53 timepoint 53 antigen PSA levels 53 chronic HCV infection 53 hemoglobin A1C 53 Viral Load 53 coinfection 53 IFN α 53 serum calcium 53 antiretroviral treatment 53 hepatitis C genotype 53 HCV infection 53 genital ulcers 53 HPV-#/# 53 transgene expression 53 TMC# r 53 cobicistat 53 IFN alpha 53 nevirapine Viramune 53 active antiretroviral therapy 53 μg dose 53 NRTIs 53 alanine aminotransferase 53 IDX# 53 blood glucose levels 53 suppressive therapy 53 dose ritonavir 53 thyroglobulin 53 pCR 53 pyrazinamide 53 A1C 53 creatinine clearance 53 HBeAg positive patients 53 HIV 53 nephrotoxicity 53 amprenavir 53 iPTH 53 hemoglobin A1c HbA1c 53 CMV disease 53 -#.# log# 53 NAbs 53 nucleoside naive 53 clodronate 53 telbivudine 53 pg mL 53 HbA 1c levels 53 serum sodium 53 Pharmacokinetics PK 53 glucocorticoid 53 g dL 52 CD# upregulation 52 IgG 52 hemoglobin Hb 52 HBV infection 52 primary endpoint 52 administered subcutaneously 52 A1c 52 posaconazole 52 fasting plasma glucose 52 infliximab 52 rilpivirine 52 genotypic 52 replicon 52 lopinavir ritonavir Kaletra 52 AZT zidovudine Retrovir 52 HAQ DI 52 mg/m2 dose 52 darunavir r 52 FTC TDF 52 serum PSA 52 plasma pharmacokinetics 52 nitazoxanide 52 serum clusterin levels 52 dose cohort 52 urate levels 52 Aptivus ® 52 APTIVUS 52 mg QD 52 pharmacodynamic 52 interferon alpha 52 serum uric acid 52 posttransplant 52 uninfected 52 interferon ribavirin 52 A1c levels 52 Prostate Specific Antigen PSA 52 serum IGF 52 HCV genotypes 52 -#.# log# copies mL 52 Crohn Disease Activity 52 fasting glucose levels 52 PEG IFN 52 docetaxel 52 sunitinib 52 genital ulcer disease 52 ribavirin RBV 52 bronchodilation 52 elvitegravir 52 cEVR 52 plus ribavirin 52 Pegasys ® 52 annualized relapse 52 p = #.# [002] 52 LVEF 52 decitabine 52 homocysteine concentrations 52 d4T 52 plasma leptin 52 clinically meaningful 52 paraprotein 52 febrile neutropenia 52 Antiretroviral Therapy 52 BENICAR HCT 52 genotype 1b 52 BARACLUDE 52 serum ALT 52 procalcitonin 52 corticosteroid dose 52 bevirimat 52 triglyceride levels 52 serum phosphate levels 52 hemagglutination inhibition HAI 52 peg IFN 52 iPrEx study 52 hsCRP levels 52 leukocyte count 52 mcg kg 52 μmol L 52 infectivity 52 P = .# 52 Ribavirin 52 anti retroviral therapy 52 monotherapy 52 nanomolar 52 HCV Genotype 52 PegIFN RBV 52 glycosylated hemoglobin HbA1c 52 pegIFN 52 NNRTIs 52 autoantibody levels 52 hemoglobin levels 52 ng ml 52 steroid dexamethasone 52 Ad5 immunity 52 achieved statistical significance 52 placebo 52 AZT 3TC 52 resected pancreatic cancer 52 alpha 2a 51 complete cytogenetic 51 evaluable patients 51 specific antigen PSA 51 serum potassium levels 51 IGFBP 51 ALT normalization 51 seroprevalence 51 CCyR 51 PASI scores 51 gout flares 51 combination antiretroviral therapy 51 glycated hemoglobin HbA1c 51 antiretrovirals 51 lamivudine refractory patients 51 RNA copies mL 51 REYATAZ ® 51 QTcF 51 creatinine 51 PEG Interferon lambda 51 SCIg 51 PSA nadir 51 serum aminotransferase levels 51 TPV r 51 Index CDAI 51 HBeAg negative patients 51 DermaVir Patch 51 zidovudine lamivudine 51 Peg IFN 51 dose dexamethasone 51 ug dose 51 bortezomib 51 IPSS 51 dose regimen 51 anticoagulation 51 serum CRP 51 mucosal healing 51 boosted atazanavir 51 glycosylated hemoglobin 51 cells uL 51 IV bisphosphonates 51 lopinavir r arm 51 glycemia 51 serum albumin 51 paricalcitol 51 Infected Patients 51 investigational protease inhibitor 51 IgG antibody 51 primary efficacy endpoint 51 undetectable virus HCV 51 viral RNA 51 certolizumab 51 lactate dehydrogenase 51 DAS# [002] 51 incontinence episodes 51 chlorambucil 51 eosinophil count 51 tiotropium 51 HIV HCV coinfected 51 HBV 51 valganciclovir 51 abacavir 51 biochemical recurrence 51 immunological responses 51 co trimoxazole 51 #mg QD [002] 51 adalimumab Humira 51 pharmacokinetic profile 51 CIMZIA TM 51 Valcyte 51 ibandronate 51 serum LDL cholesterol 51 virologic breakthrough 51 systolic blood pressure 51 serum antibody 51 aminotransferases 51 topotecan 51 boosted protease inhibitor 51 plus methotrexate 51 serum calcium levels 51 treatment naive genotype 51 MADRS score 51 baseline A1C 51 granulocyte 51 μg ml 51 SHBG levels 51 IFN gamma 51 mg BID 51 virological 51 IgA 51 tropism 51 retinal thickness 51 Ritonavir 51 ng dL 51 prospectively defined 51 tenofovir DF 51 serum vitamin D 51 plasma renin activity 51 NRTI resistance 50 serum lipid levels 50 noninferiority 50 atheroma volume 50 piperacillin tazobactam 50 antitumor effect 50 CDAI 50 p = 50 ATACAND 50 dosing cohorts 50 evaluable subjects 50 systolic dysfunction 50 interferon alfa 50 Telbivudine 50 interferon gamma 50 serum phosphorous 50 VIRAMUNE 50 elevated ALT 50 treatment naïve genotype 50 hepatic fibrosis 50 #mg dose [002] 50 serum cholesterol 50 chlamydial infection 50 chronic HCV 50 severe rotavirus gastroenteritis 50 serostatus 50 Hepsera 50 imatinib 50 HSCT 50 virologically suppressed 50 INTELENCE 50 hemoglobin A1c levels 50 demonstrated statistically significant 50 troponin T 50 IELT 50 peg interferon 50 transcriptase inhibitor NNRTI 50 β blocker 50 serum cortisol 50 unboosted 50 Darunavir 50 pegylated interferon alpha 50 nadir CD4 cell 50 serologic 50 calculated creatinine clearance 50 pharmacokinetics PK 50 SVR# 50 bilirubin levels 50 PREZISTA ritonavir 50 ACR# response 50 OADs 50 secondary endpoint 50 adiponectin concentrations 50 atazanavir Reyataz 50 antigen 50 atazanavir sulfate 50 sitagliptin 50 NATRECOR ® 50 integrase inhibitor 50 SIV infected 50 serum phosphorus levels 50 timepoints 50 rituximab 50 mcg BID 50 albumin excretion 50 CRp 50 antibody 50 trastuzumab Herceptin ® 50 virologic failures 50 CDAI score 50 follicle stimulating hormone FSH 50 hours postdose 50 mg ustekinumab 50 dose limiting toxicities 50 efavirenz Sustiva 50 eculizumab therapy 50 postexposure prophylaxis 50 #mg QD [001] 50 NRTI backbone 50 rapid virological response 50 heavily pretreated 50 dose cytarabine 50 pharmacokinetics 50 VZV 50 LDL C 50 #.#/#.# mmHg [001] 50 bcr abl 50 MOTIVATE 50 oral FTY# 50 HER2 expression 50 undetectable hepatitis C 50 CCR5 tropic 50 azacitidine 50 viremic 50 FOLFOX6 50 clusterin 50 mitoxantrone 50 alfa 2a 50 albuminuria 50 relapsed MM 50 active comparator 50 Amplicor 50 zidovudine 50 fasting glucose 50 statistical significance 50 serum PTH 50 etravirine 50 blood Phe 50 Raltegravir 50 K#R [002] 50 transaminase levels 50 M#V mutation 50 Bcl xL 50 tolerability 50 fasting blood glucose 50 insulin detemir 50 #.#/#.# mm Hg [003] 50 moderate renal impairment 50 EPZICOM 50 mcg mL 50 HbA 1c 50 liver transplant recipients 50 serum prostate 50 Hb 50 serum IgG 50 baseline LDH 50 doxorubicin docetaxel 50 CrCl 50 Hb levels 50 K#N 50 estimated glomerular filtration 50 protease inhibitor mutations 50 NNRTI resistant virus 50 Rapid Virologic Response 50 Traficet EN 50 suppress viral replication 50 Elitek 50 Viread Emtriva 50 initiating HAART 50 CIN3 50 dosing frequency 50 blood glucose concentrations 50 Epivir 50 aspartate aminotransferase 50 dapagliflozin plus 50 mRNA expression 50 gp# [001] 50 CCL#L# 50 systemic absorption 50 mammographic density 50 cTnT 50 superinfection 49 antiviral potency 49 antiretroviral drugs 49 ascending dose 49 Secondary endpoints include 49 lipid lowering therapy 49 selenium supplementation 49 ug mL 49 statistically significant 49 CC genotype 49 antihypertensive medications 49 immune reconstitution 49 posttreatment 49 Natalizumab 49 ACTH 49 ertapenem 49 initiating antiretroviral therapy 49 DAPT 49 inflammatory biomarkers 49 mL/min/#.# m 2 49 pegylated interferon alfa 49 coinfected patients 49 potent antiviral 49 ng mL 49 Naive Patients 49 endogenous EPO 49 achieved ACR# 49 Kaplan Meier estimate 49 H. pylori infection 49 maraviroc 49 trastuzumab 49 NPH insulin 49 ZFN modified cells 49 peak plasma concentrations 49 pharmacokinetic PK profile 49 NT proBNP concentrations 49 dosing 49 TNFalpha 49 spontaneous preterm delivery 49 lamivudine zidovudine 49 UGT#A# * 49 glycosylated hemoglobin levels 49 STELARA ® 49 hepatitis B immunoglobulin 49 MS relapses 49 CK # plasma concentrations 49 tumor recurrence 49 fasting insulin 49 dsDNA 49 mcg doses 49 lymphopenia 49 Virologic failure 49 postprandial glucose 49 μg doses 49 #mg/day [001] 49 locoregional disease 49 PBMCs 49 secondary efficacy endpoints 49 response CCyR 49 Virological 49 spontaneous bowel movements 49 anti leukemic 49 bezafibrate 49 fluvastatin 49 Gag Pol 49 mediated immunity 49 genital secretions 49 solifenacin 49 neurologic progression 49 virus HBV 49 Viread 49 linezolid 49 imipenem 49 intracranial hemorrhage ICH 49 mycophenolate mofetil 49 human immunodeficiency virus 49 mg RDEA# 49 PREZISTA rtv 49 lung function 49 tamoxifen therapy 49 enzymatic activity 49 viral tropism 49 lymphocytosis 49 protease inhibitors 49 activated partial thromboplastin 49 Therapy HAART 49 palivizumab 49 FUZEON 49 immunosuppression 49 platelet aggregation 49 aciclovir 49 p = #.# [004] 49 AZOR 49 triglyceride concentrations 49 calcitriol 49 lipid levels 49 mIU ml 49 neutralizing antibody responses 49 AST ALT 49 postprandial glycemia 49 parasitemia 49 3TC lamivudine Epivir 49 ApoB 49 cytokine 49 valopicitabine 49 K ras mutations 49 REYATAZ ritonavir 49 single dose nevirapine 49 zidovudine AZT 49 p = #.# [003] 49 free survival PFS 49 Lupuzor ™ 49 absolute lymphocyte 49 mg dL 49 mesalamine granules 49 HER2/neu 49 imetelstat 49 nonnucleoside reverse transcriptase inhibitors 49 plasma cortisol 49 QTc prolongation 49 immunosuppressant therapy 49 nucleoside analog 49 cytotoxicity 49 receiving antiretroviral therapy 49 aminotransferase ALT 49 daunorubicin 49 Tipranavir 49 antitumor activity 49 S/GSK# 49 Lp PLA2 49 Treatment Naive HIV 49 antihypertensive therapy 49 teriflunomide 49 reach statistical significance 49 #mg BID [001] 49 mRCC 49 antiretroviral ARV therapy 49 concomitant medications 49 mIU L 49 CANCIDAS 49 PrEP 49 Actilon 49 hepatitis B infection 49 Sustained Virologic Response 49 BRAF mutation 49 Sustained virologic response 49 cotrimoxazole prophylaxis 49 clinically meaningful improvement 49 inhibitor RG# 49 vWF 49 Kinoid 49 pharmacodynamic PD 49 tumor shrinkage 49 left ventricular ejection 49 Molecular Weight Heparin 49 COMBIVIR 49 transdermal estradiol 49 gliclazide 49 hepcidin 49 telomere length 49 ImmuKnow 49 tolerated dose MTD 49 aPTT 49 achieved sustained virological 49 rifapentine 49 KRAS mutation 49 FVIII 49 canakinumab 49 #mg BID [003] 49 GeoVax vaccine 49 sUA levels 49 Saquinavir 49 mmHg systolic 49 cortisol concentrations 49 β blockers 49 alpha defensins 49 ritonavir boosted protease inhibitor 49 #mg ATC 49 SCr 49 HIV uninfected 49 nmol liter 49 autoantibody 49 PlGF 49 HIV prevalence 49 FOXP3 49 Chronic Hepatitis C 49 dosing regimens 49 myeloperoxidase 49 stavudine 49 CR nPR 49 antiretroviral regimens 49 liver biopsy 49 triiodothyronine 49 #mg dose [001] 49 poly ICLC 49 protease inhibitors PIs 49 EpCAM expression 49 pharmacodynamics 49 BCG vaccinated 49 parasitaemia 49 liver metastases 48 GnRH agonist 48 fasting triglyceride levels 48 #mg dose [003] 48 LANTUS R 48 celgosivir 48 REYATAZ R 48 LTBI 48 hemagglutination inhibition 48 tirofiban 48 oxycodone CR 48 IgG antibodies 48 peginterferon alfa 48 hepatic insulin sensitivity 48 Pegylated Interferon 48 hsCRP 48 clinically relevant 48 immunological 48 low expressors 48 efavirenz EFV 48 albumin excretion rate 48 HBV infections 48 dose colchicine 48 oral ibandronate 48 5-FU/LV 48 corrected QT interval 48 Peginterferon 48 insulin degludec 48 serum retinol 48 Victoza R 48 olmesartan 48 neoadjuvant chemotherapy 48 CLL cells 48 symptom onset 48 tolvaptan 48 dosage regimens 48 Index CDAI score 48 tamsulosin 48 urine NGAL 48 intravascular hemolysis 48 blood phenylalanine Phe 48 Adalimumab 48 genotypes 48 amoxicillin clavulanate 48 Phase 2a trial 48 chlamydial 48 RASSF1A 48 #.#ng/ml 48 bone resorption 48 statistical significance p 48 serum BDNF 48 pharmacodynamic effects 48 CCR5 antagonist 48 Median progression 48 IGFBP 3 48 Lopinavir 48 evaluable 48 hour bronchodilation 48 mIU mL 48 triacylglycerol 48 inotropic 48 H pylori 48 Immunohistochemical analysis 48 nucleoside naive patients 48 rindopepimut 48 p = .# [002] 48 tenofovir Viread 48 HCV replication 48 azathioprine 48 pentoxifylline 48 inflammatory lesions 48 ritonavir boosted lopinavir 48 reactogenicity 48 immunosuppressive agents 48 ORENCIA 48 CD8 T cell 48 HCV antibodies 48 monoinfected 48 rifampicin 48 urinary excretion 48 Median survival 48 mg kg 48 hepatoma 48 receiving VICTRELIS 48 TMC# [002] 48 HCV SPRINT 48 hepatitis C infection 48 oral rivaroxaban 48 candidemia 48 Secondary efficacy endpoints 48 transcriptase inhibitors NNRTIs 48 ORMD 48 N. gonorrhoeae 48 prostate specific 48 ritonavir Norvir 48 nocturnal hypoglycaemia 48 rhGH 48 recurrent VTE 48 factor G CSF 48 homocysteine levels 48 antiangiogenic therapy 48 leukocytosis 48 HCV RESPOND 2 48 trough FEV1 48 HCV antibody 48 Victoza ® 48 intramuscular dose 48 cardiac biomarkers 48 cTnT levels 48 MELD score 48 advanced adenoma 48 inhibit replication 48 hematologic toxicity 48 DMARD 48 Free Survival PFS 48 OGTT 48 intermittent dosing 48 Insulin sensitivity 48 REYATAZ 48 acetazolamide 48 standard chemotherapy regimen 48 tenofovir emtricitabine 48 D dimer 48 antibody titres 48 tapentadol ER 48 d dimer 48 chronic HCV genotype 48 receiving APTIVUS r 48 mutated K ras 48 REYATAZ r arm 48 ramipril 48 univariate analysis 48 tenofovir gel 48 anti Xa 48 splenectomized patients 48 liver enzyme 48 Recurrence Score 48 ELISPOT 48 isoniazid 48 secondary endpoints 48 pegylated interferon alfa 2b 48 lipid lowering drugs 48 pulmonary exacerbations 48 mg doses 48 % CI #.#-#.# [003] 48 tumor regression 48 DAS# [001] 48 Tindamax R 48 QTc intervals 48 asthma exacerbations 48 COPD exacerbations 48 cotrimoxazole 48 plasma folate 48 #mg/m# [002] 48 metabolic parameters 48 postvaccination 48 CD# + [002] 48 co receptor tropism 48 vancomycin 48 Disease Progression 48 telomerase activity 48 MELD scores 48 Tolerability

Back to home page